Mesenchymal Stem Cells Have New Cell Culture Environment
BILLERICA, Mass., Feb. 8, 2012 /PRNewswire/ — BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the availability of the new BD Mosaic(TM) Mesenchymal Stem Cell Serum-Free (hMSC SF), a complete cell culture environment for human mesenchymal stem cells (hMSCs) derived from bone marrow.
The BD Mosaic hMSC cell culture environment is designed to provide cell expansion in a shorter culture time–about half the time of traditional serum-based media. Starting with a low minimum seeding density (3,000-4,000 cells / cm2), BD Mosaic can achieve two or more doublings per passage without re-feeding between passages. Such performance can help deliver experimental results faster and lower total cost, as well as reduce handling and potential contamination.
“An intrinsic property of mesenchymal stem cells is their ability to differentiate into various somatic tissues,” said Gregory Crescenzi, Marketing Manager, BD Biosciences. “Mesenchymal Stem Cells expand using the BD Mosaic hMSC SF cell culture environment and reliably retain their multipotency, even after many passages.”
The performance provided by the BD Mosaic hMSC cell culture environment, coupled with its lot-to-lot consistency, can offer reliable results with speed and confidence. The serum-free composition lessens variability and potential contamination events to further streamline the cell culture process and reduce risk.
The BD Mosaic hMSC cell culture environment includes the expansion medium, a media supplement and an advanced cell culture surface coating. It is the first product in BD’s line of next-generation environments for the expansion of stem cells.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
SOURCE BD (Becton, Dickinson and Company)